

2009**January**

AACR

Mouse Models of Cancer
Jan. 12-15, San Francisco, CA
www.aacr.org

AACR

Advances in Prostate Cancer Res.
Jan. 21-24, San Diego, CA
www.aacr.org

Keystone Symp.
Multiple Sclerosis

Jan. 21-26, Santa Fe, NM
keystonesymposia.org/9A8

February

DIA

Comparability Challenges: Issues in the
Assessment of Biopharmaceuticals
Feb. 3, Arlington, VA
diahome.org

DIA

Excellence in Pharmacovigilance
Feb. 9, Paris, France
diahome.org

Roy. Pharma. Soc. of Great Britain
Stability Testing of Pharmaceuticals
Feb. 9-11, Cambridge, UK
rpsgb.org/worldofpharmacy/events

Keystone Symp.

Neurodegenerative Diseases: New
Molecular Mechanisms
Feb. 17-22, Keystone, CO
keystonesymposia.org/9J5

Keystone Symp.

Axonal Connections: Molecular Cues for
Development & Regeneration
Feb. 17-22, Keystone, CO
keystonesymposia.org/9J6

Keystone Symp.

Neurobiology of Pain & Analgesia
Feb. 22-27, Santa Fe, NM
keystonesymposia.org/9J5

Keystone Symp.

Dissecting the Vasculature
Feb. 24 – Mar. 1, Vancouver, BC,
Canada
keystonesymposia.org

Cambridge Healthtech Inst.
5th Ann. Translational Medicine
Feb. 25-27, San Francisco, CA
healthtech.com

DIA

3rd Ann. Conf. on Drug Discovery &
Clinical Development in India
Feb. 25-28, Mumbai, India
diahome.org

Biophysical Soc.

53rd Ann. Mtg.
Feb. 28 – Mar. 4, Boston, MA
www.biophysics.org/2009meeting

March

Joint Pharma. Analysis Group
Clinical Trials Directive: Five Years On
Mar. 5, London, UK
jpag.org

Roy. Pharma. Soc. of Great Britain
Traditional Herbal Medicines
Mar. 6, London, UK
rpsgb.org

DIA

24th Ann. Data Conf. & Exhibit.
Mar. 9, Philadelphia, PA
diahome.org

Assn. Pharmacie Galénique Industrielle
Skin & Formulation, 3rd Symp.
Mar. 9-10, Versailles, France
apgi.org/skin.htm

Roy. Pharma. Soc. of Great Britain
Travel Medicine
Mar. 12, London, UK
www.rpsgb.org/events

NAVBO

Vascular Matrix Biology & Bioengineering
Workshop
Mar. 16-19, Whistler, BC, Canada
navbo.org/VMBB2009

DIA

21st Ann. EuroMtg.
Mar. 23-25, Berlin, Germany
diahome.org

5th Intl. Symp. on CD1 and NKT Cells

Mar. 23-27, Kamakura, Japan
Email: kaki@rcai.riken.kp

April

ASPET

G-Protein Targets
Apr. 17-18, New Orleans, LA
aspet.org/public/meetings/G-Protein_09.htm

APS, ASBMB, ASPET, ASIP, ASN, AAA
Experimental Biology '09

Apr. 18-22, New Orleans, LA
www.faseb.org/meetings

AACR

100th Ann. Mtg.
Apr. 18-22, Denver, CO
www.aacr.org

4th Neurotoxicity Soc. Mtg.

Apr. 24-26, Arica, Chile
neurotoxicitysociety.org

ACCP/ESCP

Intl. Cong. on Clinical Pharmacy &
Pharmacotherapy Prep. Course
Apr. 24-28, Orlando, FL
accp.com

Collegium Intl. Neuro-

Psychopharmacologicum (CINP)
Major Psychoses & Substance Abuse
Apr. 25-27, Edinburgh, UK
cinp.org

Roy. Pharma. Soc. of Great Britain

Development of Veterinary Meds.
Apr. 27, London, UK
rpsgb.org

Croatian Soc. for Neuroscience

Neurogenomics & Neuroimaging of
Developmental Disorders
April 30 – May 5, Dubrovnik, Croatia
www.depol.org

May

Amer. Assn. of Immunologists
96th Ann. Mtg.
May 8-12, Seattle, WA
www.faseb.org/meetings

Roy. Pharma. Soc. of Great Britain
Advanced Level Workshop on
Pharmacokinetic-Pharmacodynamic Data
Analysis
May 17-21, Cambridge, UK
rpsgb.org/events

Canadian Pain Soc.
Ann. Conf.
May 27-30, Quebec City, PQ, Canada
canadianpainsociety.ca

June

Canadian Soc. for Pharma. Sci.
12th Ann. Symp.
June 3-6, Toronto, ON, Canada
cspscanada.org

Intl. Behavioral Neuroscience Soc.
Ann. Mtg.
June 9-14, Manzanillo, Mexico
ibnshomepage.org

Endocrine Soc.
9th Ann. Mtg.
June 10-13, Washington, DC
endo-society.org

Protein Soc.
VIII European Symp.
June 14-18, Zurich, Switzerland
proteinsociety.org

DIA
45th Ann. Mtg.
June 21-25, San Diego, CA
diahome.org

5th Intl. Symp. on Peptide Receptors &
Kinin 2009 (Joint Mtg.)
June 26-30, 2009, Quebec City, Canada
peptidereceptors.net

Intl. Soc. for Cerebral Brain Flow &
Metabolism
24th Intl. Symp. on Cerebral Blood Flow,
Metabolism & Function and
9th Intl. Conf. on Quantification of Brain
Function with PET
June 29 – July 3, Chicago, IL
www.kenes.com/brain

July

Intl. Soc. for Stem Cell Res.
7th Ann. Mtg.
July 8-11, Barcelona, Spain
isscr.org

Intl. Soc. on Thrombosis & Haemostasis
22nd Cong.
July 11-16, Boston, MA
isth2009.com

Intl. Acad. of Cardiology
15th World Cong. on Heart Disease
July 18-21, Vancouver, BC, Canada
cardiologyonline.com

36th Intl. Congr. Physiological Sci.
July 27 – Aug. 1, Kyoto, Japan
www.iups2009.com

August

Inter-Amer. Soc. of Hypertension
XVIII Scientific Sessions
Aug. 5-8, Belo Horizonte, MG, Brazil
sbh.org.br/iash2009

Intl. Soc. for Pharmacoepidemiology
25th Anniv. Intl. Conf. on
Pharmacoepidemiology & Therapeutic
Risk Mngmnt.
Aug. 16-19, Providence, RI
pharmacoepi.org

Korean Soc. for Brain & Neural Sci.
22nd Biennial Mtg. of the ISN/APSN
Aug. 23-28, Busan, Korea
isn2009.org

September

ASBMR
38th Ann. Mtg.
Sept. 11-15, Denver, CO
asbmr.org

Amer. Col. of Clin. Pharmacol.
38th Ann. Mtg.
Sept. 13-15, San Antonio, TX
accp1.org

NAVBO
Workshop on Genetics & Genomics of
Vascular Diseases
Sept. 14-17, Hyannis, MA
navbo.org

October

DIA
Special Training Course on US Regulatory
Affairs
Oct. 19, Basel, Switzerland
diahome.org

Soc. for Neurosci.
Ann Mtg.
Oct. 24-28, Chicago, IL
sfn.org

November

Ann. Biomed. Res. Conf. for Minority
Students
Nov. 4-7, Phoenix, AZ
www.abrcms.org

December

Paragon Conventions
2nd Intl. Conf. on Fixed Combination
in the Treatment of Hypertension,
Dyslipidemia & Diabetes Mellitus
Dec. 10-12, Valencia, Spain
paragon-conventions.com/fixed09

18th WRN World Cong. on Parkinson's
Disease & Related Disorders
Dec. 13-16, Miami Beach, FL
kenes.com/parkinson

2010

February

EDDP 2010 – Intl. Conf. on Early Disease
Detection & Prevention
Feb. 25-28, Munich, Germany
paragon-conventions.com/eddp2010

April

AACR
Annual Mtg.
Apr. 17-21, Washington, DC
www.aacr.org

APS, ASBMB, ASPET, ASN, AAA
Experimental Biology '10
Apr. 24-28, Anaheim, CA
www.faseb.org/meetings

May

ARVO
Ann. Mtg.
May 2-6, Ft. Lauderdale, FL
www.arvo.org

June

Collegium Intl. Neuro-
Psychopharmacologicum (CINP)
2010 World Congress
June 6-10, Hong Kong, China
www.cinp2010.com

NAVBO
16th Intl. Vascular Biol. Mtg.
June 19-23, Los Angeles, CA
navbo.org

July

Intl. Union of Toxicology
XII Intl. Cong. of Toxicology
July 11-15, Barcelona, Spain
iutox2010.org

August

Symp. of Protein Soc.
Aug. 1-5, San Diego, CA
proteinsociety.org

Japanese Soc. for Immunology
14th Intl. Congr. of Immunology
Aug. 22-27, Kobe, Japan
www.ici2010.org

November

Amer. Soc. of Human Genetics
Ann. Mtg.
Nov. 2-6, Washington, DC
ashg.org

Soc. for Neurosci.
Ann. Mtg.
Nov. 13-17, San Diego, CA
sfn.org

Intl. Pharmaceut. Fed. & AAPS
FIP Pharma. Sci. World Congr.
Nov. 14-18, New Orleans, LA
pswc2010.org

Does Your Library Subscribe to *Molecular Interventions*?



6.000 Impact Factor



Scientifically Rigorous
and cutting edge
content keeps you up to
date in all areas related
to pharmacology. With
meaningful graphics
and exciting content,
EVERYONE should be
reading *MI*!!

**TELL YOUR LIBRARIAN TO
SUBSCRIBE TODAY!!**

**2009 Subscription prices now
available at:**

<http://molinterv.aspetjournals.org>



Outliers



"'DRINK CLEAR LIQUIDS', MY DOCTOR SAID."

Molecular Interventions Instructions to Authors

Revised September 28, 2007

Scope of Submitted Manuscripts

Papers published in **Molecular Interventions** are generally invited by the Editor after consideration of recommendations from the Editorial Advisory Board. Others who have an interest in writing for **Molecular Interventions** are encouraged to send proposals to the Editor. The proposal should include a detailed outline of the proposed article and a brief curriculum vitae. Articles in **Molecular Interventions** deal mainly with the current status of the subject under review. They are to be written clearly and concisely and should be intelligible to nonspecialists, with definitions of unfamiliar technical terms and explanations of difficult or controversial points included. At the same time, the review is to be sufficiently precise and detailed to command the attention and respect of experts in the field. Selective rather than exhaustive coverage of the literature is requested. Previous reviews of the subject and of related fields should be cited. Authors are asked to be critical of methods, results, and conclusions and to challenge accepted concepts where warranted. Conflicting points of view are to be presented objectively in good perspective. Deficiencies in the field may be pointed out and avenues for further work may be indicated. The usual length ranges between 8 and 12 printed pages, corresponding to about 24 to 36 manuscript pages. Diagrams, tables, and illustrations should be included to bring out new concepts and important relationships. The Art Director will work with the author to further develop graphics for the article.

Submission of Manuscripts

Submit three (3) collated hard copies of each manuscript (including illustrations) as well as an electronic version to

Dr. Harry B. Smith, Editor
Molecular Interventions
ASPET
9650 Rockville Pike
Bethesda, MD 20814-3995

telephone: 301-634-7790
fax: 301-634-7061
e-mail: hsmith@aspet.org

Diskettes produced on PC or Mac platforms are acceptable. Microsoft Word is preferred. Authors preparing diskettes on Macintosh computers should not use the Fast Save option. Other formats and files in ASCII can be used, but are not encouraged. Identify the diskette by providing the journal name, first author's name, manuscript title, name of computer file, type of hardware, operating system and version number, and software program and version number. Authors are encouraged to supply a digital copy of their illustrations. Image files should be submitted by e-mail or on zip disks (formatted for Mac or PC) or CDs; TIFF and EPS formats are strongly preferred. Illustrations created in Adobe Illustrator, Freehand, or Corel Draw should be saved in EPS format.

A completed copy of the **Molecular Interventions** Copyright Transfer form signed by all authors should be included with the manuscript at the time of submission (available from the online version of these *Instructions to Authors*). Submission of a manuscript amounts to assurance that it has received proper clearance from the author's company or institution, that it has not been copyrighted, published, or accepted for publication elsewhere, that it is not currently being considered for publication elsewhere, and that it will not be submitted elsewhere while under consideration by **Molecular Interventions**. The corresponding author is responsible for obtaining permission from the copyright owner to reproduce or modify figures and tables and to reproduce text (in whole or in part) from previous publications; permissions must allow electronic reproduction as well as print. A permissions request form is available online from the *Instructions to Authors*. The signed permissions must be submitted with the manuscript and be identified as to the relevant item in the manuscript (e.g., "permissions for Fig. 1"). In addition, a statement indicating that the material is being reprinted with permission must be included in the relevant figure legend or table footnote of the manuscript. Reprinted text must be enclosed in quotation marks, and the permission statement must be included as running text or indicated parenthetically.

Manuscripts must be in English, typewritten and double spaced throughout, including references, tables, and figure legends, using only one side of 8 1/2 by 11 inch (ca. 216 by 280 mm) paper, with at least 1 inch (25 mm) margins, and the copies must be collated. Pages should not be stapled. Three (3) sets of figures should be submitted, including one original set (see Figures). Three copies (3) of papers reporting any potentially overlapping earlier work (including relevant "in press" papers) must be included. Rejected manuscripts, figures, and original drawings will not be returned unless specifically requested at the time of submission.

Organization of the Manuscript

Manuscripts should contain the following sections in the order listed. Each section should begin on a new page and all pages should be numbered consecutively.

1. **Title page.** This should contain the complete title of the article, the names of all authors, and full contact information for corresponding author (address, phone, fax, e-mail). Financial support for the research should be indicated as an unnumbered footnote to the title and included with other footnotes on a separate page following the References section. A running title and at least five keywords should also be given.

2. **Abstract.** The abstract should be approximately 100 words, and should provide the context in which the topic of the article should be appreciated. The abstract should be intelligible to the general reader without reference to text. Reference citations are not permitted in abstracts, and nonstandard abbreviations should not be included.

3. **Body of manuscript.** It is highly recommended that the body be divided into conceptual sections, the first of which should be labeled INTRODUCTION and the last of which should be labeled CONCLUSIONS. Section headings should be given in all capital letters, subsection headings in standard title format, and sub-subsection headings in italics.

4. **Acknowledgments.** The Acknowledgments section is placed at the end of the text.

5. **References.** References are cited in the text by number. In the reference list, the references should be arranged in the order in which they are first cited in the text. The names of all authors should be given in the reference list. Abbreviations for journals should conform to the Medline abbreviation list, which is available from the online *Instructions to Authors*. References to personal communications, unpublished observations, and papers submitted for publication are given in parentheses at the appropriate location in the text, not in the list of references. Only papers that have been officially accepted for publication may be cited as "in press" in the reference list. The authors are responsible for the accuracy of the references. The format for journal article, chapter, and book references is as follows:

1. Griffiths, R.R., Bigelow, G.E., and Liebson, I.A. Human coffee drinking: Reinforcing and physical dependence producing effects of caffeine. *J. Pharmacol. Exp. Ther.* **239**, 416-425 (1997).

2. Chernow, B. and O'Brian, J.T. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (Ziegler, M.G. and Lake, C.R. eds) pp 439-449, Williams & Wilkins, Baltimore (1984).

3. Tallarida, R.J. and Murray, R.B. *Manual of Pharmacologic Calculations with Computer Programs*. Springer-Verlag, New York (1987).

6. **Tables.** Each table must be on a separate page. The tables are numbered consecutively with Arabic numerals, and designed to fit the column or page size of the journal. A brief descriptive title is provided at the top of each table. General statements about the table follow the title in paragraph form. Footnotes to tables are referenced by italicized, lower case, superscript letters (a, b, c, etc.) and defined beneath the table.

7. **Legends for figures.** Figures are numbered consecutively with Arabic numerals, with each one displayed on a separate page. Legends must provide sufficient explanation for the reader to understand the figure independent of the text.

8. **Figures.** Submit illustrations as glossy photographs, original India-ink drawings, or high-resolution laser printer output. Lettering on figures should be large enough to be legible after reduction to single-column width of 21 picas (about 3.5 inches or 9 cm). Letter typesizes after reduction should be 6-8 points. Do not use varying letter typesizes within a single figure; use the same size or similar sizes throughout the drawing. Figures should be ready, in all respects, for direct reproduction. All panels of a multipart figure should be provided on the same page. Although each of the manuscript copies should contain a complete set of figures, only the originals need be of the quality suitable for reproduction. In the case of halftones, three sets of photographs are required. If symbols are not explained on the face of the figure, only standard print characters may be used. The back of each figure should bear its number, the name of the first author, and the word TOP at the appropriate edge. Include figure titles in the legend and not on the figure itself. Photomicrographs and electron micrographs must be labeled with a magnification calibration in micrometers or Angstrom units. A statement concerning the magnification must appear in the figure legend.

9. **Author Photographs.** Supply a black-and-white or color glossy photograph of each author. Head size (top of head to bottom of chin) should be no smaller than 1.5 inches tall; also allow generous room on all sides for cropping. Write full name on back of photos; identify multiple authors as necessary.

10. **Additional images.** All authors are encouraged to submit images to be considered for use on the cover of **Molecular Interventions**. Cover images should be submitted as glossy (8x10) prints, transparencies or negatives, or as high-resolution digital files. Cover submissions should be accompanied by a 100-word description of the image. In addition, the title of each review article will be highlighted by an image selected by the editorial office; authors are encouraged to supply images with an appropriate caption for title treatment. Consult a recent issue of **Molecular Interventions** for examples.

Abbreviations, Drug Names, Gene Names, Etc

All abbreviations and technical nomenclature should be explained in parentheses upon their first use in the text. Do not abbreviate terms (other than standard abbreviations) that are used less than three times in the text. Generic drug names are used in text, tables, and figures. Trade names may be given in parentheses following the first text reference, but should not appear in titles, figures, or tables. Whereas trade names are capitalized, generic or chemical names are not.